

**Title of the Clinical Trial:** Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence

**Sponsor:** European Organisation for Research and Treatment of Cancer (EORTC)

**EORTC protocol number:** 22071-24071

**EudraCT number:** 2008-006180-36

**Protocol:** version 2.1 dated June 22, 2010

**Concerning:** Premature end of trial.

Dear madam/sir,

EORTC Study 22071-24071 was discontinued before any enrolment of patients.

This unfortunate decision is based on the fact that, according to the recently presented results of the RTOG 0522 trial, the concurrent administration of cetuximab to chemoradiation does not result in any benefit for patients with unresected head and neck squamous cell cancer. Since panitumumab binds to the same epitope of the EGF-receptor as cetuximab, testing the same concept in the adjuvant setting, using panitumumab instead of cetuximab, is not of interest for the company (Amgen).

Unfortunately, all efforts made by the EORTC to find a solution to continue this study in a different setting were unsuccessful.

We also confirm hereby that at present no patients were ever screened, randomised or treated.

Please note that all participating Investigators / sites have been informed about this premature end of trial by the sponsor.

Yours sincerely,  
EORTC Headquarters

